Lung cancer combo trial halted early: what happened?
NCT ID NCT06267001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding tiragolumab to atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB to IIIB). The trial was terminated early, so results are limited. The main goal was to check safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji
Bakirkoy / Istanbul, 34147, Turkey (Türkiye)
-
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
-
Changzhou First People's Hospital
Changzhou, 213003, China
-
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, 60336-232, Brazil
-
E-DA Hospital
Kaohsiung City, 824, Taiwan
-
Hiroshima University Hospital
Hiroshima, 734-8551, Japan
-
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
-
Hospital de Cancer de Barretos
Barretos, São Paulo, 14784-400, Brazil
-
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, 99010-260, Brazil
-
Instytut Gruzlicy I Chorob Pluc
Warsaw, 01-138, Poland
-
Kindai University Hospital
Osaka, 589-8511, Japan
-
Korea University Guro Hospital
Seoul, 08308, South Korea
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
-
Liaoning Provincial Cancer Hospital
Shengyang, 110042, China
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, 210008, China
-
National Taiwan University Cancer Center
Zhongzheng Dist., 106, Taiwan
-
Ningbo No.2 Hospital
Ningbo, DUMMY_VALUE, China
-
Nucleo de Oncologia da Bahia - NOB
Salvador, Bahia, Estado de Bahia, 40170-380, Brazil
-
Ospedale P. Pederzoli Casa di cura Privata
Peschiera Del Garda (VR), Veneto, 37019, Italy
-
Pusan National University Hospital
Busan, 602-739, South Korea
-
Pusan National University Yangsan Hospital
Gyeongsangnam-do, 50612, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, 463-707, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Shandong Cancer Hospital
Jinan, 250117, China
-
St. Vincent's Hospital
Gyeonggi-do, 16247, South Korea
-
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
-
Taichung Veterans General Hospital
Taichung, 407, Taiwan
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, 510080, China
-
Tianjin Cancer Hospital
Tianjin, 300060, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430030, China
-
Vajira Hospital
Bangkok, 10300, Thailand
-
Yunnan Cancer Hospital
Kunming, 650118, China
-
Zhejiang Cancer Hospital
Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
- New study aims to tame cholesterol side effect of lung cancer drug